YOLT 203
Alternative Names: YOLT-203Latest Information Update: 25 Jul 2024
At a glance
- Originator YolTech Therapeutics
- Class Gene therapies; Uricosurics
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Hyperuricaemia
Most Recent Events
- 19 Jul 2024 RenJi Hospital plans a phase 0 trial for Primary-hyperoxaluria-type-1 (In children, In adolescents, In adults, In the elderly) in China (IV) (NCT06511349)
- 25 Oct 2023 Preclinical trials in Hyperuricaemia in China (Parenteral), prior to October 2023 (YolTech Therapeutics pipeline, October 2023)